Resources
NPLB partners with leading health economists, innovators, investors, and academics to conduct research and generate insights that help everyone understand healthcare and the biomedical innovation ecosystem.
Our team builds on this work to create clear and concise explainers, videos, and other materials that advance our mission to defend biomedical affordability and innovation.
Presentations
FEATURED WEBINAR
How the IRA makes new small molecule biotech R&D uninvestable for diseases of aging
By price setting small molecule medicines after only 9 years on the market, the Inflation Reduction Act threatens investments in future cures. The law’s disparate treatment of small and large molecules will warp R&D and result in fewer new cures, particularly those for cancer and other diseases of aging.
Videos
FEATURED VIDEO
The Value of Medicines
Medicines do so much more than help the patient that's treated today. Considering a drug's societal value shows we may value them a lot more than we had thought.
Research
FEATURED RESEARCH
Valuing the Societal Impact of Medicines and Other Health Technologies: A User Guide to Current Best Practices
A new paper published in Forum for Health Economics & Policy by twelve leading health economists explains why the conventional math used to value medicines falls short, and it lays out a consensus “user’s guide” for operationalizing overlooked elements of societal value.
Advocacy
FEATURED CONTENT
Do more for patients, preserve innovation: Fix the Inflation Reduction Act
1000+ Investors, researchers, patients, & innovators urge critical fixes to Senate Rx Bill that can, in a budget neutral way, lower Medicare Rx out-of-pocket costs and preserve biomedical research and development of both small molecule treatments and biologics.
We’re building support across the biotech ecosystem
BECOME A FIRST RESPONDER & THOUGHT PARTNER
Sign up to receive action alerts. Help protect access to lifesaving medicines & preserve innovation for those still waiting for a cure.